Absci (ABSI) Net Income towards Common Stockholders Growth (3y) (2023 - 2026)

Absci (ABSI) Net Income towards Common Stockholders Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - 84.25%
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -10.84%
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 26.38%
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - 34.98%
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -46.86%
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 13.80%
9 Abivax 91.96 Bn 91.96 Bn - -
10 Absci 1.13 Bn 1.01 Bn - -8.22%

Historic Data

Download Data
DateValue
Mar 31, 2026 -8.22%
Dec 31, 2025 -14.93%
Sep 30, 2025 -1.74%
Jun 30, 2025 -2.15%
Mar 31, 2025 3.69%
Dec 31, 2024 -4.82%
Sep 30, 2024 -4.69%
Jun 30, 2024 16.32%
Mar 31, 2024 -22.49%
Dec 31, 2023 -60.27%
Sep 30, 2023 -19.27%
Jun 30, 2023 -34.90%